Aspirin may help prevent return of precancerous esophagus condition

NCT ID NCT02521285

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether taking aspirin can prevent Barrett's esophagus from returning after it has been successfully removed with radiofrequency ablation. Researchers will measure levels of a protein linked to Barrett's in tissue samples from 21 participants over 12 months. The goal is to see if aspirin can keep the condition away safely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aspirin
What this could lead to: If it works, this could point toward a simple, low-cost way to prevent Barrett's esophagus from coming back after treatment.
What could go wrong: This is a very small, early-phase trial (21 people) looking at biomarkers, not whether cancer actually develops. Aspirin can cause bleeding, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARRETT ESOPHAGUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus Barrett esophagus esophageal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BARRETT ESOPHAGUS ESOPHAGEAL ADENOCARCINOMA

Contacts and locations

Locations

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030, United States
Kansas City Veterans Affairs Medical Center

Kansas City, Missouri, 64128, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Northwestern University

Chicago, Illinois, 60611, United States
Saint Michael's Hospital

Toronto, Ontario, M5B 1W8, Canada
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States
UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Pennsylvania/Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.